{
    "clinical_study": {
        "@rank": "57022", 
        "arm_group": {
            "arm_group_label": "Domperidone/ a proton pump inhibitor/metoclopramide users", 
            "description": "Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole,    lansoprazole, esomeprazole, rabeprazole, and pantoprazole."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this observational study is to assess the risk of out-of-hospital Sudden\n      Cardiac (heart) Death (SCD) associated with current use of domperidone compared to current\n      use of a Proton Pump Inhibitor (PPI), current use of metoclopramide, or non-use of any of\n      these medications."
        }, 
        "brief_title": "An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Death, Sudden, Cardiac", 
        "condition_browse": {
            "mesh_term": [
                "Death", 
                "Death, Sudden", 
                "Death, Sudden, Cardiac"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a population-based, retrospective (a study in which the exposures and outcomes\n      occurred before the study began), and nested case-control study (a study in which the\n      patients with the study outcome [cases] and comparison patients without that outcome\n      [controls] are observed to assess their exposure to the medication being studied\n      [domperidone, PPI's and metoclopramide]). The data will come from the United Kingdom's\n      Clinical Practice Research Datalink. The study will estimate the rate of SCD during periods\n      of exposure to each of the study medications, and during periods of exposure to none of\n      them; and the ratios of these rates. It will also use a \"case-crossover\" analysis (in which\n      each case serves as his/her own control) to re-estimate these rate ratios in a manner that\n      takes account of personal characteristics such as obesity or smoking that may affect the\n      study findings and are incompletely recorded in the database."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        - Patients registered in English practices whose data are linkable to Hospital Episode\n        Statistics (HES) and Office for National Statistics, UK (ONS). Patients are required to\n        have at least 1 year in the Clinical Practice Research Datalink before they can enter the\n        study\n\n        Exclusion criteria:\n\n          -  Patients with a diagnosis of cancer other than non-melanoma skin cancer\n\n          -  Patients from practices not linkable to HES and ONS data\n\n          -  Patient time corresponding to the period between hospital admission date and 30 days\n             after discharge date"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with exposure to domperidone, proton pump inhibitor, and metoclopramide"
            }
        }, 
        "enrollment": {
            "#text": "15000", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907633", 
            "org_study_id": "CR102051", 
            "secondary_id": [
                "RRA-7880", 
                "Epi 316"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Domperidone/ a proton pump inhibitor/metoclopramide users", 
            "description": "This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug", 
            "other_name": "Motilium"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Domperidone", 
                "Metoclopramide", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Death, Sudden, Cardiac", 
            "Risk of Sudden Cardiac Death", 
            "Domperidone", 
            "Proton Pump Inhibitors (PPI)", 
            "Metoclopramide", 
            "Observational Study"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "number_of_groups": "1", 
        "official_title": "Post-Authorization Safety Study: Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide", 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "This will  be evaluated for the number of study participants (who had SCD) exposed to domperidone, proton pump inhibitor, metoclopramide, and none of these medications. SCD is defined as a natural death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia (irregular heartbeat).", 
                "measure": "Number of out-of-hospital sudden cardiac death (SCD) associated with the exposure to domperidone, proton pump inhibitor, metoclopramide, and none of these medications", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }, 
            {
                "description": "This will be evaluated for the number of study participants who had SCD in relation to domperidone exposure period and domperidone non-exposure period. SCD is defined as a natural death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia (irregular heartbeat). This will be analyzed by case-crossover method (self-matching design) which will be adjusted for personal characteristics that vary little over time in each individual. eg, for obesity.", 
                "measure": "Number of out-of-hospital Sudden Cardiac Death (SCD) in relation to domperidone exposure period and domperidone non-exposure period", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }, 
            {
                "description": "This will be evaluated for the number of study participants who had SCD in relation to PPI exposure period and PPI non-exposure period. SCD is defined as a natural death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia (irregular heartbeat). This will be analyzed by case-crossover method (self-matching design) which will be adjusted for personal characteristics that vary little over time in each individual. eg, for obesity.", 
                "measure": "Number of out-of-hospital Sudden Cardiac Deaths (SCD) in relation to Proton Pump Inhibitor (PPI) exposure period and PPI non-exposure period", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }, 
            {
                "description": "This will be evaluated for the number of study participants who had SCD in relation to metoclopramide exposure period and metoclopramide non-exposure period. SCD is defined as a natural death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia (irregular heartbeat). This will be analyzed by case-crossover method (self-matching design) which will be adjusted for personal characteristics that vary little over time in each individual. eg, for obesity.", 
                "measure": "Number of out-of-hospital Sudden Cardiac Deaths (SCD) in relation to metoclopramide exposure period and metoclopramide non-exposure period", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907633"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}